Lubiprostone

Chloride Channel Activator — ALIMENTARY TRACT AND METABOLISM

Key facts

Lubiprostone is an ofp drug in the Chloride Channel Activator class catalogued in DrugCentral. It was first approved by the FDA in 2006. Its mechanism of action is classified as Chloride Channel Activators. DrugCentral lists 1 molecular target, including CLCN2. Recorded indications include Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.

• Approval status: ofp (first approved 2006 by the FDA).
• Drug class: Chloride Channel Activator.
• Mechanism of action: Chloride Channel Activators.
• Molecular targets: CLCN2 (1 listed in DrugCentral).
• Indications: Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.
• ATC code: A06AX03 (Other drugs for constipation).
• Molecular formula: C20H32F2O5; molecular weight 390.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Chronic idiopathic constipation
• Irritable bowel syndrome characterized by constipation

Contraindications (3)

• Gastrointestinal obstruction
• Pregnancy, function
• Severe diarrhea

Mechanism & targets

• Mechanism of action (MoA): Chloride Channel Activators
• Established pharmacologic class: Chloride Channel Activator

Molecular targets (1)

Target	Gene	Action	Activity
Chloride channel protein 2	CLCN2	opener	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2006-01-31	FDA	—	SUCAMPO PHARMA LLC

ATC classification

ATC code	Therapeutic hierarchy
A06AX03	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Other drugs for constipation

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ileus	68.2
Constipation	66.9
Hepatic function abnormal	60.2
Chest discomfort	59.5
Dyspnoea	55.0
Urine chloride decreased	49.7
Toxic optic neuropathy	43.1
Pneumonia aspiration	42.4
Marasmus	41.7
Decreased appetite	40.1
Urine sodium decreased	39.1
Drug intolerance	37.4

Chemical structure

• Molecular formula: C₂₀H₃₂F₂O₅
• Molecular weight: 390.47 g/mol
• CAS number: 333963-40-9
• InChIKey: WGFOBBZOWHGYQH-MXHNKVEKSA-N
• PubChem CID: 157920

CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(O)=O)O1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lubiprostone used for?

DrugCentral lists the following indications for Lubiprostone: Chronic idiopathic constipation and Irritable bowel syndrome characterized by constipation.

How does Lubiprostone work?

Lubiprostone is classified as Chloride Channel Activators; its molecular targets in DrugCentral include CLCN2 (opener).

When was Lubiprostone first approved?

Lubiprostone was first approved by the FDA in 2006.

What drug class does Lubiprostone belong to?

Lubiprostone is in the Chloride Channel Activator class.

What is the chemical formula of Lubiprostone?

Lubiprostone has the molecular formula C20H32F2O5 and a molecular weight of 390.47 g/mol.

Sources

• DrugCentral drug card 4123 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201134 — compound record and bioactivity
• PubChem CID 157920 — chemical identifiers
• DrugBank DB01046 — drug record
• FDA UNII 7662KG2R6K — substance identity
• DailyMed: FDA labels for Lubiprostone — current prescribing information (label search)
• UniProt P51788 (CLCN2) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.